MedTrace Logo

TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection

NCT02588755 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-03-31

No results posted yet for this study

Summary

The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection

Conditions

  • Intrahepatic Cholangiocarcinoma

Interventions

PROCEDURE

TACE+Tegafur

Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.

PROCEDURE

TACE

TACE alone

Sponsors & Collaborators

  • Eastern Hepatobiliary Surgery Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02588755 on ClinicalTrials.gov